US Pharma MarketingExamine the real-world timelines of the FDA’s CNPV pathway. Discover how Commissioner’s National Priority Vouchers are reshaping drug development strategies. By Laura Knighton, Thomas Pataillot-Meakin, Max Larkinson and Furkan Guvenc at Lifescience Dynamics June 19, 2026 Unlike Priority Review Vouchers (PRVs), CNPVs are non-transferable and permit enhanced pre-submission requests with the FDA, facilitating an expedited rolling review process conceptually similar to elements of the RTOR program. Companies are encouraged to apply through a simplified form , with justification limited to 350 words – notably less complex than standard application processes associated with other expedited pathways. Vouchers are awarded on…
The FDA’s Commissioner’s National Priority Voucher (CNPV) pilot program was announced in June 2025 to reduce review times for drug and biological products down to 1-2 months compared with 6+ months for conventional drug and biological product applications by implementing a “tumor board” style review process. The program was envisioned to expedite review process of…
The post CNPV: A gamechanger for the pharma industry or simply more chaos? appeared first on Drug Discovery and Development.
Source: Drug Discovery & Development